Genetic Signatures

Genetic Signatures Gross Profit

The Gross Profit of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is -12.72 M AUD. In the previous year, Gross Profit was 7.78 M AUD — a change of -263.46% (lower).

Gross Profit

-12.72 MAUD

YoY

-263.46%

Last updated:

Gross Profit of Genetic Signatures is 2026 -12.72 M AUD. Gross Profit of Genetic Signatures was 2025 7.78 M AUD. It decreases by -263.46% lower compared to the previous year.

The Genetic Signatures Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2019
4.16 M AUD
Jan 1, 2020
-2.37 M AUD
Jan 1, 2021
4.27 M AUD
Jan 1, 2022
7.21 M AUD
Jan 1, 2023
-12.74 M AUD
Jan 1, 2024
4.31 M AUD
Jan 1, 2025
7.78 M AUD
Jan 1, 2026
-12.72 M AUD
The Genetic Signatures Gross Profit history
YEARGross ProfitYoY
-12.72 MAUD-263.46%
7.78 MAUD+80.66%
4.31 MAUD-133.82%
-12.74 MAUD-276.64%
7.21 MAUD+68.90%
4.27 MAUD-280.55%
-2.37 MAUD-156.81%
4.16 MAUD+38.26%
3.01 MAUD+28.78%
2.34 MAUD+3.93%
2.25 MAUD+247.11%
648,123.00AUD-5.50%
685,831.00AUD-586.36%
-141,012.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genetic Signatures Revenue

Genetic Signatures Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
35.42 M AUD
2.97 M AUD
3.06 M AUD
Jan 1, 2023
16.94 M AUD
-18.89 M AUD
-14.05 M AUD
Jan 1, 2024
9.77 M AUD
-22.33 M AUD
-17.86 M AUD
Jan 1, 2025
15.90 M AUD
-18.48 M AUD
-20.10 M AUD
Jan 1, 2026
14.45 M AUD
-17.74 M AUD
-14.01 M AUD
Jan 1, 2027 (e)
23.70 M AUD
-16.48 M AUD
-14.76 M AUD
Jan 1, 2028 (e)
30.80 M AUD
-19.65 M AUD
-10.22 M AUD
Jan 1, 2029 (e)
141.60 M AUD
-107.01 M AUD
0.00 AUD

Genetic Signatures Margins

Genetic Signatures stock margins

The Genetic Signatures margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genetic Signatures. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genetic Signatures.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
20.36 %
8.38 %
8.65 %
Jan 1, 2023
-75.21 %
-111.52 %
-82.96 %
Jan 1, 2024
44.11 %
-228.68 %
-182.90 %
Jan 1, 2025
48.95 %
-116.23 %
-126.44 %
Jan 1, 2026
-88.02 %
-122.76 %
-96.91 %
Jan 1, 2027 (e)
-88.02 %
-69.52 %
-62.30 %
Jan 1, 2028 (e)
-88.02 %
-63.80 %
-33.19 %
Jan 1, 2029 (e)
-88.02 %
-75.57 %
0.00 %

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Gross Profit of Genetic Signatures is -12.72 M AUD in 2026.

Gross Profit of Genetic Signatures changed from 7.78 M AUD to -12.72 M AUD, representing a -263.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Genetic Signatures

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Genetic Signatures